共 50 条
Risk of subsequent lower respiratory tract infection (LRTI) after hospitalization for COVID-19 LRTI and non-COVID-19 LRTI: a retrospective cohort study
被引:1
|作者:
Bruxvoort, Katia J.
[1
,2
]
Fischer, Heidi
[1
]
Lewnard, Joseph A.
[3
,4
,5
]
Hong, Vennis X.
[1
]
Pomichowski, Magdalena
[1
]
Grant, Lindsay R.
[6
]
Jodar, Luis
[6
]
Gessner, Bradford D.
[6
]
Tartof, Sara Y.
[1
]
机构:
[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 90027 USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, 1665 Univ Blvd, Birmingham, AL 35233 USA
[3] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA USA
[5] Univ Calif Berkeley, Coll Engn, Ctr Computat Biol, Berkeley, CA USA
[6] Pfizer Vaccines, Collegeville, PA USA
来源:
关键词:
Pneumonia;
Lower respiratory tract infection;
COVID-19;
Hospitalization;
COMMUNITY-ACQUIRED PNEUMONIA;
PNEUMOCOCCAL CONJUGATE VACCINE;
ADVISORY-COMMITTEE;
UNITED-STATES;
UPDATED RECOMMENDATIONS;
RECURRENT PNEUMONIA;
IMMUNIZATION;
ADULTS;
EPIDEMIOLOGY;
D O I:
10.1186/s41479-023-00117-5
中图分类号:
R56 [呼吸系及胸部疾病];
学科分类号:
摘要:
Background Respiratory pathogens, including SARS-CoV-2, can cause pulmonary structural damage and physiologic impairment, which may increase the risk of subsequent lower respiratory tract infections (LRTI). Prior hospitalization for any reason is a risk factor for LRTI, but data on the risk of subsequent new-onset LRTI following hospitalization for COVID-19 LRTI or non-COVID-19 LRTI are needed to inform strategies for immunizations targeting respiratory pathogens.Methods We conducted a retrospective cohort study at Kaiser Permanente Southern California (KPSC) among adults hospitalized from 3/1/2020 to 5/31/2022, excluding labor and delivery. We categorized individuals into 3 mutually exclusive baseline exposure groups: those hospitalized for COVID-19 LRTI, those hospitalized for non-COVID-19 LRTI, and those hospitalized for all other causes without LRTI or COVID-19 ("non-LRTI"). Following hospital discharge, patients were followed up for new-onset LRTI, beginning 30 antibiotic-free days after hospital discharge until 8/31/2022. We used multivariable cause-specific Cox regression with time-varying covariates to estimate hazard ratios (HR) of new-onset LRTI comparing those hospitalized for COVID-19 LRTI or non-COVID-19 LRTI to those hospitalized for non-LRTI, adjusting for demographic and clinical characteristics.Results The study included 22,417 individuals hospitalized for COVID-19 LRTI, 12,795 individuals hospitalized for non-COVID-19 LRTI, and 176,788 individuals hospitalized for non-LRTI. Individuals hospitalized for non-COVID-19 LRTI were older and had more comorbidities than those hospitalized for COVID-19 LRTI or non-LRTI. Incidence rates per 1,000 person-years (95% CI) of new-onset LRTI were 52.5 (51.4-53.6) among individuals hospitalized for COVID-19 LRTI, 253.5 (243.7-263.6) among those hospitalized for non-COVID-19 LRTI, and 52.5 (51.4-53.6) among those hospitalized for non-LRTI. The adjusted hazard of new-onset LRTI during follow-up was 20% higher among individuals hospitalized for COVID-19 LRTI (HR 1.20 [95% CI: 1.12-1.28]) and 301% higher among individuals hospitalized for non-COVID-19 LRTI (HR 3.01 [95% CI: 2.87-3.15]) compared to those hospitalized for non-LRTI.Conclusion The risk of new-onset LRTI following hospital discharge was high, particularly among those hospitalized for non-COVID-19 LRTI, but also for COVID-19 LRTI. These data suggest that immunizations targeting respiratory pathogens, including COVID-19, should be considered for adults hospitalized for LRTI prior to hospital discharge.
引用
收藏
页数:10
相关论文